较小的环状灰质调解了双重任务步态和事件痴呆症之间的关联
Pauline Ali1,2,3, Frederico Pieruccini-Faria4,5, Cédric Annweiler1,6,7
1Department of Medical Biophysics, Schulich School of Medicine & Dentistry, Western University, North London, Ontario, N6A 5C1, Canada.
Brain : a journal of neurology
|November 5, 2024
概括
轻度认知障碍和高双重任务步行成本的个体面临痴呆症风险增加了三倍. 这种风险是由右侧前带皮层和中带皮层的灰色物质体积损失解释的,识别了潜在的治疗点.
科学领域:
- 神经科学是一个神经科学.
- 老年学是指老年学的学科.
- 生物标志物 生物标志物
背景情况:
- 轻度认知障碍 (MCI) 的高双任务步行成本与痴呆症风险增加三倍有关.
- 这种关联背后的特定大脑区域在很大程度上是未知的,这阻碍了识别潜在的治疗点.
研究的目的:
- 调查大脑灰质量和运动皮质代谢物水平是否解释了MCI患者双重任务步行成本和发病性痴呆症之间的联系.
- 确定与双重任务步行成本和痴呆症进展相关的特定皮质区域.
主要方法:
- 对139名患有MCI的个体进行了长度研究,随访9年,定期进行认知,步态和MRI评估.
- 在单一和双重任务条件下测量的步行表现 (倒数,命名动物,连续七).
- 双重任务成本计算为步行速度的百分比变化;用于评估灰质体积和代谢物水平的调度分析.
主要成果:
- 在特定的认知任务中,高的双重任务步行成本 (≥20%) 与几个大脑结构中的灰质体积较小有关.
- 在右前带皮层和中带皮层的灰质体积损失中介于双重任务步行成本和痴呆风险 (48%的影响) 之间的关联.
- 没有观察到通过其他大脑区域或运动皮层代谢物水平的调解.
结论:
- 右前带皮层和中带皮层灰质体积较小,解释了MCI中高双任务步行成本和发病性痴呆症之间的关联.
- 这突出了认知衰退中的认知运动相互作用的神经机制,并支持双重任务下的步态,作为潜在的痴呆症生物标志物.
更多相关视频
07:42Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
Published on: December 16, 2022
2.9K
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
7.9K
相关概念视频
Role of Cerebellum and Prefrontal Cortex in Memory
375
The cerebellum, while traditionally associated with motor control, also plays a crucial role in memory, particularly in procedural memory, which involves learning motor tasks that become automatic through repetition. For example, studies have shown that when the cerebellum is damaged, individuals or animals lose the ability to learn conditioned motor responses, such as the conditioned eye-blink response in classical conditioning experiments with rabbits. This study demonstrates the...
375
Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
